Market Overview

UPDATE: Goldman Sachs Reinstates Neutral on BioMed Realty as Acquisitions Broaden Their Portfolio

Related BMR
TRACON Pharmaceuticals Completes $27M Financing And Expands Management Team And Board of Directors
MLV Initiates Coverage On Healthcare REIT Sector

In a report published on Friday, Goldman Sachs analyst Matthew Rand reinstated a Neutral rating on BioMed Realty (NYSE: BMR) and maintained its $21 price target on the company.

In the report, Goldman Sachs commented that, "We have removed the Not Rated designation from BioMed Realty shares. We rate BMR as a Neutral, with a 12-month, $21 price target. We continue to think that BMR's most relevant comp is Alexandria Real Estate Equities (ARE), which we also rate Neutral. In addition, we think that Digital Realty Trust (DLR, Buy) offers better value as well as better growth within the more capital-intensive, slow-growth property sectors."

BioMed Realty closed on Thursday at $20.50

Latest Ratings for BMR

DateFirmActionFromTo
Aug 2014Stifel NicolausMaintainsBuy
Jun 2014MLVInitiates Coverage onHold
Apr 2014Stifel NicolausMaintainsBuy

View More Analyst Ratings for BMR
View the Latest Analyst Ratings

Posted-In: Goldman Sachs Matthew RandAnalyst Color Reiteration Analyst Ratings

 

Related Articles (BMR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters